The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1506
ISSUE 1506
October 24, 2016
Issue 1506
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Lipid-Lowering Drugs
October 24, 2016 (Issue: 1506)
Lipid-lowering drugs should be taken indefinitely;
when they are stopped, plasma lipoproteins return to
pretreatment levels. HMG-CoA reductase inhibitors
(statins) remain the drugs of choice for treatment of
most patients who require...more
- NJ Stone et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2889.
- AJ Garber et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract 2016; 22:84.
- TA Jacobson et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 2015; 9:129.
- Writing Committee et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol 2016; 68:92.
- S Yusuf et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374:2021.
- CTT Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670.
- CP Cannon et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387.
- JR Guyton et al. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 2014; 8:S72.
- HV Ganga et al. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014; 168:6.
- SEARCH Collaborative Group et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376:1658.
- ES Stroes et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36:1012.
- MJ Tikkanen et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168:3846.
- N Sattar et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375:735.
- D Preiss et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305:2556.
- K Axsom et al. Statins and diabetes: the good, the bad, and the unknown. Curr Atheroscler Rep 2013; 15:299.
- JS McKinney and WJ Kostis. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012; 43:2149.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44. Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed October 13, 2016.
- R Elsby et al. Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos 2016; 44:398.
- MG Silverman et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016; 316:1289.
- Pitavastatin (Livalo) – the seventh statin. Med Lett Drugs Ther 2010; 52:57.
- CA Dujovne et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90:1092.
- RH Knopp et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24:729.
- Alirocumab (Praluent) to lower LDL-cholesterol. Med Lett Drugs Ther 2015; 57:113.
- Evolocumab (Repatha) – A second PCSK9 Inhibitor to lower LDL-cholesterol. Med Lett Drugs Ther 2015; 57:140.
- JG Robinson et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1489.
- MS Sabatine et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500.
- MS Sabatine et al. Rationale and design of the further cardiovascular outcomes research with PCSK9 Inhibition in subjects with elevated risk trial. Am Heart J 2016; 173:94.
- GG Schwartz et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 2014; 168:682.
- CP Cannon et al. Relationship between major adverse cardiovascular events and achieved low-density lipoprotein cholesterol levels in Phase 3 ODYSSEY trials of alirocumab versus control. J Am Coll Cardiol 2016; 67:1867.
- S Ross et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis. Circ Cardiovasc Genet 2015; 8:618.
- Drugs for hypertriglyceridemia. Med Lett Drugs Ther 2013; 55:17.
- HB Rubins et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410.
- ACCORD Study Group et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563.
- AB Goldfine et al. Fibrates in the treatment of dyslipidemias – time for a reassessment. N Engl J Med 2011; 365:481.
- FDA. AbbVie Inc. et al; withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Federal Register 2016 April 18; 81 FR 22612. Docket No. FDA-2016-N-1127.
- E Bruckert et al. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210:353.
- HPS2-THRIVE Collaborative Group et al. Effects of extendedrelease niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371:203.
- DM Lloyd-Jones. Niacin and HDL cholesterol--time to face facts. N Engl J Med 2014; 371:271.
- Fish oil supplements. Med Lett Drugs Ther 2012; 54:83.
- Risk and Prevention Study Collaborative Group. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013; 368:1800.
- SM Kwak et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012; 172:686.
- Icosapent ethyl (Vascepa) for severe hypertriglyceridemia. Med Lett Drugs Ther 2013; 55:33.
- DJ Rader and JJ Kastelein. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014; 129:1022.
- Two new drugs for homozygous familial hypercholesterolemia. Med Lett Drugs Ther 2013; 55:25.
- FJ Raal et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:341.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1506
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.